These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 32621419)

  • 21. Rotavirus NSP1 Associates with Components of the Cullin RING Ligase Family of E3 Ubiquitin Ligases.
    Lutz LM; Pace CR; Arnold MM
    J Virol; 2016 Jul; 90(13):6036-48. PubMed ID: 27099313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer drug discovery by targeting cullin neddylation.
    Yu Q; Jiang Y; Sun Y
    Acta Pharm Sin B; 2020 May; 10(5):746-765. PubMed ID: 32528826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
    Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
    Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skp2 in the ubiquitin-proteasome system: A comprehensive review.
    Asmamaw MD; Liu Y; Zheng YC; Shi XJ; Liu HM
    Med Res Rev; 2020 Sep; 40(5):1920-1949. PubMed ID: 32391596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
    Nguyen HC; Wang W; Xiong Y
    Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for Cullins and RING component inhibition: Targeting E3 ubiquitin pathway conductors for cancer therapeutics.
    Shafique S; Ali W; Kanwal S; Rashid S
    Int J Biol Macromol; 2018 Jan; 106():532-543. PubMed ID: 28802844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.
    Villeneuve NF; Lau A; Zhang DD
    Antioxid Redox Signal; 2010 Dec; 13(11):1699-712. PubMed ID: 20486766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.
    Zhao Y; Sun Y
    Neoplasia; 2012 May; 14(5):360-7. PubMed ID: 22745582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Destiny for Degradation: Interplay between Cullin-RING E3 Ligases and Autophagy.
    Lu G; Wang L; Zhou J; Liu W; Shen HM
    Trends Cell Biol; 2021 Jun; 31(6):432-444. PubMed ID: 33573849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.
    Jang SM; Redon CE; Aladjem MI
    Front Mol Biosci; 2018; 5():19. PubMed ID: 29594129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Protein Neddylation for Cancer Therapy.
    Zhou L; Jia L
    Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of cell senescence by targeting to Cullin-RING Ligases (CRLs) for effective cancer therapy.
    Pan Y; Xu H; Liu R; Jia L
    Int J Biochem Mol Biol; 2012; 3(3):273-81. PubMed ID: 23097743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases.
    Ying J; Zhang M; Qiu X; Lu Y
    Cancer Chemother Pharmacol; 2018 May; 81(5):797-808. PubMed ID: 29450620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
    Zhou W; Xu J; Tan M; Li H; Li H; Wei W; Sun Y
    Mol Cell; 2018 Jun; 70(6):1008-1024.e6. PubMed ID: 29932898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining the Effects of Neddylation on Cullin-RING Ligase-Dependent Protein Ubiquitination.
    Wang K; Liu X
    Curr Protoc; 2022 Mar; 2(3):e401. PubMed ID: 35316580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting SCF E3 Ligases for Cancer Therapies.
    Liu J; Peng Y; Zhang J; Long J; Liu J; Wei W
    Adv Exp Med Biol; 2020; 1217():123-146. PubMed ID: 31898226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy.
    Bano I; Malhi M; Zhao M; Giurgiulescu L; Sajjad H; Kieliszek M
    3 Biotech; 2022 Apr; 12(4):103. PubMed ID: 35463041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neddylation-CRLs regulate the functions of Treg immune cells.
    Wu D; Sun Y
    Bioessays; 2023 Apr; 45(4):e2200222. PubMed ID: 36709423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.